Transcriptional analysis of CXCR4, DNMT3A, DNMT3B and DNMT1 gene expression in primary advanced uterine cervical carcinoma

International Journal of Oncology

Volumn 40, Issue 3, 2012, Pages 860-866

  Łuczak, Michał W ^a   Roszak, Andrzej ^a   Pawlik, Piotr ^a   Kȩdzia, Helena ^a   Kȩdzia, Witold ^a   Malkowska Walczak, Blanka ^a   Lianeri, Margarita ^a   Jagodziński, Paweł P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cervical cancer; CXCR4; DNMTs; HIF 1A; Hypoxia

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADULT; ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; POLAND; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; UTERINE CERVIX CARCINOMA;

CELL HYPOXIA; COHORT STUDIES; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENOMICS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RECEPTORS, CXCR4; TRANSCRIPTION, GENETIC; UTERINE CERVICAL NEOPLASMS;

EID: 84857182486     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1183     Document Type: Article

References (67)

1. Liyanage SH, Roberts CA and Rockall AG: MRI and PET scans for primary staging and detection of cervical cancer recurrence. Womens Health 6: 251-267, 2010.
2. Smith JS, Lindsay L, Hoots B, et al: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121: 621-632, 2007. (Pubitemid 46986496)
3. Kisseljov F, Sakharova O and Kondratjeva T: Cellular and molecular biological aspects of cervical intraepithelial neoplasia. Int Rev Cell Mol Biol 271: 35-95, 2008.
4. Łuczak MW and Jagodziński PP: The role of DNA methylation in cancer development. Folia Histochem Cytobiol 44: 143-154, 2006.
5. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003. (Pubitemid 37448928)
6. Payne SR and Kemp CJ: Tumor suppressor genetics. Carcinogenesis 26: 2031-2045, 2005. (Pubitemid 41672190)
7. Momparler RL: Cancer epigenetics. Oncogene 42: 6479-6483, 2003.
8. Robertson KD: DNA methylation, methyltransferases, and cancer. Oncogene 24: 3139-3155, 2001.
9. Bestor TH: The DNA methyltransferases of mammals. Hum Mol Genet 16: 2395-2402, 2000.
10. Cedar H: DNA methylation and gene activity. Cell 53: 3-4, 1988.
11. Mayer W, Niveleau A, Walter J, Fundele R and Haaf T: Demethylation of the zygotic paternal genome. Nature 403: 501-502, 2000. (Pubitemid 30082186)
12. Jost JP, Oakeley EJ, Zhu B, et al: 5-Methylcytosine DNA glycosylase participates in the genome-wide loss of DNA methylation occurring during mouse myoblast differentiation. Nucleic Acids Res 29: 4452-4461, 2001. (Pubitemid 33064786)
13. Szyf M, Pakneshan P and Rabbani SA: DNA methylation and breast cancer. Biochem Pharmacol 68: 1187-1197, 2004. (Pubitemid 39094284)
14. Kristensen LS, Nielsen HM and Hansen LL: Epigenetics and cancer treatment. Eur J Pharmacol 625: 131-142, 2009.
15. Kanai Y: Alterations of DNA methylation and clinicopathological diversity of human cancers. Pathol Int 58: 544-558, 2008.
16. Kanai Y and Hirohashi S: Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancer to a malignant state. Carcinogenesis 28: 2434-2442, 2007. (Pubitemid 350238944)
17. Miremadi A, Oestergaard MZ, Pharoah PD and Caldas C: Cancer genetics of epigenetic genes. Hum Mol Genet 16: R28-R49, 2007. (Pubitemid 47241841)
18. Au Yeung CL, Tsang WP, Tsang TY, Co NN, Yau PL and Kwok TT: HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53. Oncol Rep 24: 1599-1604, 2010.
19. Laurson J, Khan S, Chung R, Cross K and Raj K: Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 31: 918-926, 2010.
20. Lin TS, Lee H, Chen RA, et al: An association of DNMT3b protein expression with P16INK4a promoter hypermethylation in non-smoking female lung cancer with human papillomavirus infection. Cancer Lett 226: 77-84, 2005. (Pubitemid 40943432)
21. Unruh A, Ressel A, Mohamed HG, et al: The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22: 3213-3220, 2003. (Pubitemid 36712933)
22. Kaelin WG Jr and Ratcliffe PJ: Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402, 2008.
23. Maxwell PH, Wiesener MS, Chang GW, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 6733: 271-275, 1999. (Pubitemid 29246458)
24. Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ, Rodríguez-Enríquez S and Moreno-Sánchez R: HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 9: 1084-1101, 2009.
25. Weidemann A and Johnson RS: Biology of HIF-1alpha. Cell Death Differ 15: 621-627, 2008.
26. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
27. Puchtler H, Meloan SN and Waldrop FS: Application of current chemical concepts to metal-hematein and -brazilein stains. Histochemistry 85: 353-364, 1986.
28. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
29. Łuczak MW, Roszak A, Pawlik P, Kȩdzia H, Lianeri M and Jagodziński PP: Increased expression of HIF-1A and its implication in the hypoxia pathway in primary advanced uterine cervical carcinoma. Oncol Rep 26: 1259-1264, 2011.
30. Lee WY, Huang SC, Hsu KF, Tzeng CC and Shen WL: Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence. Gynecol Oncol 108: 377-384, 2008.
31. Mazibrada J, Rittà M, Mondini M, et al: Interaction between inflammation and angiogenesis during different stages of cervical carcinogenesis. Gynecol Oncol 108: 112-120, 2008. (Pubitemid 350299432)
32. Smith-McCune KK and Weidner N: Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 54: 800-804, 1994. (Pubitemid 24068340)
33. Bruick RK and McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science 5545: 1337-1340, 2001. (Pubitemid 33063099)
34. Hirsilä M, Koivunen P, Günzler V, Kivirikko KI and Myllyharju J: Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 278: 30772-30780, 2003. (Pubitemid 36994584)
35. Tuckerman JR, Zhao Y, Hewitson KS, et al: Determination and comparison of specific activity of the HIF-prolyl hydroxylases. FEBS Lett 576: 145-150, 2004. (Pubitemid 39330473)
36. Wenger RH, Stiehl DP and Camenisch G: Integration of oxygen signaling at the consensus HRE. Sci STKE. 306:re12, 2005.
37. Brat DJ, Kaur B and van Meir EG: Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front Biosci 8: D100-D116, 2003. (Pubitemid 39069966)
38. Kimura H, Weisz A, Ogura T, et al: Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J Biol Chem 276: 2292-2298, 2001. (Pubitemid 32109715)
39. 2- regulated gene expression. FASEB J 16: 1151-1162, 2002.
40. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ and Krek W: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 6955: 307-311, 2003. (Pubitemid 37158407)
41. Chik F and Szyf M: Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis 32: 224-232, 2011.
42. Ateeq B, Unterberger A, Szyf M and Rabbani SA: Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 10: 266-278, 2008. (Pubitemid 351328580)
43. Dejeux E, Rønneberg JA, Solvang H, et al: DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer 9: 68, 2010.
44. Przybylski M, Kozłowska A, Pietkiewicz PP, Lutkowska A, Lianeri M and Jagodzinski PP: Increased CXCR4 expression in AsPC1 pancreatic carcinoma cells with RNA interference-mediated knockdown of DNMT1 and DNMT3B. Biomed Pharmacother 64: 254-258, 2010.
45. Sato N, Matsubayashi H, Fukushima N and Goggins M: The chemokine receptor CXCR4 is regulated by DNA methylation in pancreatic cancer. Cancer Biol Ther 4: 70-76, 2005. (Pubitemid 41350934)
46. Kubarek Ł and Jagodzinski PP: Epigenetic up-regulation of CXCR4 and CXCL12 expression by 17 beta-estradiol and tamoxifen is associated with formation of DNA methyltransferase 3B4 splice variant in Ishikawa endometrial adenocarcinoma cells. FEBS Lett 581: 1441-1448, 2007. (Pubitemid 46463959)
47. Mori T, Kim J, Yamano T, et al: Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 65: 1800-1807, 2005. (Pubitemid 40478607)
48. + cells from patients with primary myelofibrosis. Stem Cells 26: 1920-1930, 2008.
49. Kodama J, Hasengaowa, Kusumoto T, et al: Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol 18: 70-76, 2007.
50. Zhang JP, Lu WG, Ye F, Chen HZ, Zhou CY and Xie X: Study on CXCR4/SDF-1alpha axis in lymph node metastasis of cervical squamous cell carcinoma. Int J Gynecol Cancer 17: 78-483, 2007.
51. Yang YC, Lee ZY, Wu CC, Chen TC, Chang CL and Chen CP: CXCR4 expression is associated with pelvic lymph node metastasis in cervical adenocarcinoma. Int J Gynecol Cancer 17: 676-686, 2007.
52. Rein DT, Breidenbach M, Nettelbeck DM, et al: Evaluation of tissue-specific promoters in carcinomas of the cervix uteri. J Gene Med 11: 1281-1289, 2004. (Pubitemid 40228139)
53. Tang B, Qu Y, Zhao F, et al: In vitro effects of hypoxia-inducible factor 1alpha on the biological characteristics of the SiHa uterine cervix cancer cell line. Int J Gynecol Cancer 19: 898-904, 2009.
54. La Salle S and Trasler JM: Dynamic expression of DNMT3a and DNMT3b isoforms during male germ cell development in the mouse. Dev Biol 296: 71-82, 2006. (Pubitemid 44061755)
55. Chen T, Ueda Y, Xie S and Li E: A novel Dnmt3a isoform produced from an alternative promoter localizes to euchromatin and its expression correlates with active de novo methylation. J Biol Chem 277: 38746-38754, 2002. (Pubitemid 35154737)
56. Weisenberger DJ, Velicescu M, Preciado-Lopez MA, et al: Identification and characterization of alternatively spliced variants of DNA methyltransferase 3a in mammalian cells. Gene 298: 91-99, 2002. (Pubitemid 35284266)
57. Okano M, Bell DW, Haber DA and Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257, 1999. (Pubitemid 29519904)
58. Deng T, Kuang Y, Wang L, Li J, Wang Z and Fei J: An essential role for DNA methyltransferase 3a in melanoma tumorigenesis. Biochem Biophys Res Commun 387: 611-616, 2009.
59. Ng EK, Tsang WP, Ng SS, et al: MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer 101: 699-706, 2009.
60. Daniel FI, Rivero ER, Modolo F, Lopes TG and Salum FG: Immunohistochemical expression of DNA methyltransferases 1, 3a and 3b in oral leukoplakias and squamous cell carcinomas. Arch Oral Biol 55: 1024-1030, 2010.
61. Qu Y, Mu G, Wu Y, et al: Overexpression of DNA methyltransferases 1, 3a, and 3b significantly correlates with retinoblastoma tumorigenesis. Am J Clin Pathol 134: 826-834, 2010.
62. Zhao Z, Wu Q, Cheng J, Qiu X, Zhang J and Fan H: Depletion of DNMT3A suppressed cell proliferation and restored PTEN in hepatocellular carcinoma cell. J Biomed Biotechnol ID:737535, 2010.
63. Choi SH, Heo K, Byun HM, An W, Lu W and Yang AS: Identification of preferential target sites for human DNA methyltransferases. Nucleic Acids Res 39: 104-118, 2011.
64. Robert MF, Morin S, Beaulieu N, et al: DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 33: 61-65, 2003. (Pubitemid 36068683)
65. Beaulieu N, Morin S, Chute IC, Robert MF, Nguyen H and MacLeod AR: An essential role for DNA methyltransferase DNMT3B in cancer cell survival. J Biol Chem 277: 28176-28181, 2002. (Pubitemid 34966771)
66. Sawada M, Kanai Y, Arai E, Ushijima S, Ojima H and Hirohashi S: Increased expression of DNA methyltransferase 1 (DNMT1) protein in uterine cervix squamous cell carcinoma and its precursor lesion. Cancer Lett 251: 211-219, 2007. (Pubitemid 46669793)
67. Burgers WA, Blanchon L, Pradhan S, De Launoit Y, Kouzarides T and Fuks F: Viral oncoproteins target the DNA methyltransferases. Oncogene 26: 1650-1655, 2007. (Pubitemid 46398736)